Events

S3 DIS4- Energy Innovators Matchmaking event
MAY
Thu
15

This was 1 year ago

Location

EnergyVille Genk

EnergyVille
Thor Park 8310 & 8320
3600 Genk
Programmes
Digital, Industry & Space Climate, Energy, Mobility

The Cluster TWEED and Pôles MecaTech and GreenWin are inviting you to this inter-regional Energy Innovation matchmaking between Wallonia and Flanders on May 15, in EnergyVille, Genk.

This event brings together S3 members, innovators, and enthusiasts from both Wallonia and Flanders for one-day focusing on current EU Innovation funding opportunities. Jump in to share your skills, plans and ideas and meet your future Flemish and/or Walloon partners in the B2B!

The objectives of this initiative are to : 

  1. Present regional innovation ecosystems and roadmaps – by the Clusters of innovation

  2. Present open EU call and opportunities  – by the EU call responsible

  3. Pitch some practical ideas / ask for competence to build an EU project – by project stimulator

  4. Meet the futurs project partners in B2B – by all innovation actors

More information and registration: here

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.